Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Functional (Non Ulcer) Dyspepsia Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Functional (Non Ulcer) Dyspepsia Overview | 7 | 1 |
| Pipeline Products for Functional (Non Ulcer) Dyspepsia Comparative Analysis | 8 | 1 |
| Functional (Non Ulcer) Dyspepsia Therapeutics under Development by Companies | 9 | 1 |
| Functional (Non Ulcer) Dyspepsia Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Functional (Non Ulcer) Dyspepsia Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Functional (Non Ulcer) Dyspepsia Products under Development by Companies | 14 | 1 |
| Functional (Non Ulcer) Dyspepsia Products under Investigation by Universities/Institutes | 15 | 1 |
| Functional (Non Ulcer) Dyspepsia Companies Involved in Therapeutics Development | 16 | 5 |
| Ironwood Pharmaceuticals, Inc. | 16 | 1 |
| RaQualia Pharma Inc. | 17 | 1 |
| Yuhan Corporation | 18 | 1 |
| Zensun (Shanghai) Sci &Tech Co., Ltd. | 19 | 1 |
| Zeria Pharmaceutical Co., Ltd. | 20 | 1 |
| Functional (Non Ulcer) Dyspepsia Therapeutics Assessment | 21 | 8 |
| Assessment by Monotherapy Products | 21 | 1 |
| Assessment by Target | 22 | 2 |
| Assessment by Mechanism of Action | 24 | 2 |
| Assessment by Route of Administration | 26 | 1 |
| Assessment by Molecule Type | 27 | 2 |
| Drug Profiles | 29 | 11 |
| 5-BIOP Drug Profile | 29 | 1 |
| acotiamide hydrochloride Drug Profile | 30 | 2 |
| LT-4005 Drug Profile | 32 | 1 |
| recanaclotide Drug Profile | 33 | 2 |
| RQ-00000010 Drug Profile | 35 | 2 |
| RQ-00201894 Drug Profile | 37 | 1 |
| YH-12852 Drug Profile | 38 | 1 |
| ZS-07 Drug Profile | 39 | 1 |
| Functional (Non Ulcer) Dyspepsia Dormant Projects | 40 | 1 |
| Functional (Non Ulcer) Dyspepsia Discontinued Products | 41 | 1 |
| Functional (Non Ulcer) Dyspepsia Product Development Milestones | 42 | 2 |
| Featured News &Press Releases | 42 | 1 |
| Oct 20, 2014: Ironwood Presents IW-9179 Phase IIa Data at American College of Gastroenterology 2014 Annual Scientific Meeting | 42 | 1 |
| Mar 25, 2013: Zeria Pharma Receives Approval For Acofide In Japan For Treating Functional Dyspepsia | 42 | 1 |
| Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010 | 43 | 1 |
| Appendix | 44 | 2 |
| Methodology | 44 | 1 |
| Coverage | 44 | 1 |
| Secondary Research | 44 | 1 |
| Primary Research | 44 | 1 |
| Expert Panel Validation | 44 | 1 |
| Contact Us | 44 | 1 |
| Disclaimer | 45 | 1 |